Reponex Pharmaceuticals 开始针对新型腹膜炎治疗药物 RNX-011 的关键 2 期试验。 Reponex Pharmaceuticals begins pivotal Phase 2 trial for new peritonitis treatment RNX-011.

制药公平小组的子公司Reponex制药公司A/S获得批准,开始对RNX-011进行关键的第二阶段临床试验。 RNX-011是治疗危及生命的腹膜炎的药物。 Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, has been granted approval to begin a pivotal Phase 2 clinical trial for RNX-011, a drug aimed at treating life-threatening peritonitis. 该试验将涉及32名病人,将评估该药物在减少手术后并发症和改善患者康复方面的效力。 The trial, which will involve 32 patients, will assess the drug's effectiveness in reducing postoperative complications and improving patient recovery. CEO Christian Tange强调了这一点,认为这是该公司的一个重要商业里程碑,标志着在实现主要制药伙伴所要求的数据方面迈出了重要一步。 CEO Christian Tange highlighted this as a key commercial milestone for the company, marking a significant step towards achieving data required by major pharmaceutical partners.